- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Psyence Biomedical Ltd.: Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development | 32 | GlobeNewswire (Europe) | NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or the "Company") is pleased to provide an update on its previously-announced pending strategic... ► Artikel lesen | |
| Di | Psyence Group Inc: Psyence Group, Psyence Biomed enter debt swap deal | 3 | Stockwatch | ||
| Mo | Psyence Group Inc.: Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical | 88 | GlobeNewswire (Europe) | TORONTO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) hereby announces that it has entered into a debt-for-equity swap agreement (the "Debt Swap... ► Artikel lesen | |
| 08.10. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 04.10. | Psyence Biomed halts Clairvoyant Therapeutics acquisition | 2 | Investing.com | ||
| 04.10. | Psyence Biomedical to not proceed with Clairvoyant acquisition | 1 | Seeking Alpha | ||
| 04.10. | Psyence Biomed stoppt Übernahme von Clairvoyant Therapeutics | 2 | Investing.com Deutsch | ||
| 04.10. | Psyence Biomedical Ltd.: Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant | 102 | GlobeNewswire (Europe) | NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or the "Company"), a developer of psilocybin-based therapeutics, today provided an update on its... ► Artikel lesen | |
| 02.10. | Psyence Biomedical files to sell 10.9M common shares for holders. | 2 | Seeking Alpha | ||
| 02.10. | PSYENCE BIOMEDICAL LTD. - F-1, Registration statement for certain foreign private issuers | 1 | SEC Filings | ||
| 20.09. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 19.09. | Psyence Biomed acquires stake in PsyLabs for $1.1 million | 1 | Investing.com | ||
| 19.09. | Psyence Biomedical Ltd.: Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs | 2 | GlobeNewswire (USA) | ||
| 18.09. | Psyence Group Inc.: Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones | 99 | GlobeNewswire (Europe) | Initiated Phase IIb study of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care Expanded pipeline into Alcohol Use Disorder (AUD) and Substance Use Disorders... ► Artikel lesen | |
| 16.09. | Psyence Group Inc.: Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in ... | 1 | GlobeNewswire (USA) | ||
| 16.09. | Psyence Biomedical Ltd.: Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones | 92 | GlobeNewswire (Europe) | Initiated Phase IIb study of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care Expanded pipeline into Alcohol Use Disorder (AUD) and Substance Use Disorders... ► Artikel lesen | |
| 13.09. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.09. | Psyence Biomedical receives delisting determination from Nasdaq | 1 | Seeking Alpha | ||
| 13.09. | Psyence Biomedical droht Delisting von der Nasdaq wegen zu geringer Marktkapitalisierung | 1 | Investing.com Deutsch | ||
| 13.09. | Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq | 1.374 | GlobeNewswire (Europe) | NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the "Company") (Nasdaq: PBM) announced that on September 12, 2024, the Company received a staff determination letter (the "Determination... ► Artikel lesen |
Seite:
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 39,540 | -1,20 % | DZ BANK stuft QIAGEN NV auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat die Einstufung für Qiagen auf "Kaufen" mit einem fairen Wert von 50 Euro belassen. Der Labordienstleister und Diagnostikspezialist verfüge u?ber ein ausgezeichnetes... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,17 | 0,00 % | Longboard Pharmaceuticals, Inc.: Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline | The proposed acquisition represents a significant step forward in Lundbeck's Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental... ► Artikel lesen | |
| DYNE THERAPEUTICS | 34,730 | 0,00 % | Dyne Therapeutics Reports Positive Data From Phase 1/2 DELIVER Trial Of DYNE-251 In DMD | WASHINGTON (dpa-AFX) - Tuesday, Dyne Therapeutics, Inc. (DYN) revealed new clinical findings from its Phase 1/2 DELIVER trial of DYNE-251 for patients with Duchenne muscular dystrophy also known... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 37,070 | -1,38 % | Tarsus taps actor Betsy Sodaro to embody a 'mitey problem' in 1st Xdemvy DTC TV ad | ||
| NUVALENT | 102,16 | -2,53 % | NUVL: CEO Porter James Richard verkauft Aktien und übt Optionen aus | ||
| NURIX THERAPEUTICS | 24,720 | -4,22 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update | Initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia patient population with Fast Track Designation from the FDA Initiated Phase 1b dose expansion of NX-5948 in Waldenstrom's... ► Artikel lesen | |
| EVOTEC | 5,570 | +3,05 % | Noch 26 Tage: Evotec vor Übernahme-Überraschung? | Nur noch 26 Tage bis zum Showdown: Gelingt es Evotec (WKN: 566480), im Rahmen seiner 9-Monats-Zahlen ein neues Kursfeuerwerk zu entfachen? Die Chancen stehen gut. Eine unlängst veröffentlichte Unternehmenspräsentation... ► Artikel lesen | |
| JANUX THERAPEUTICS | 49,810 | 0,00 % | Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights | SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,580 | 0,00 % | Summit Therapeutics (NASDAQ:SMMT) Trading Down 5% - Should You Sell? | ||
| HARMONY BIOSCIENCES | 34,970 | 0,00 % | Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028 | WAKIX® (pitolisant) Net Revenue of $172.8 Million for Second Quarter 2024; ~29% Growth Year-over-Year Next Generation Pitolisant High-Dose (HD) Program Advances Based on Pilot Pharmacokinetic (PK)... ► Artikel lesen | |
| HUMACYTE | 4,820 | 0,00 % | Humacyte, Inc: Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology's Kidney Week 2024 | DURHAM, N.C., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 16,130 | 0,00 % | Kathleen D. Scott Sells 12,500 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock | ||
| ARCTURUS THERAPEUTICS | 20,600 | 0,00 % | Pad Chivukula Sells 12,000 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock | ||
| DAY ONE BIOPHARMACEUTICALS | 15,080 | +0,47 % | Day One Biopharmaceuticals, Inc.: Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024 | ||
| ADMA BIOLOGICS | 16,135 | 0,00 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang |
PSYENCE BIOMEDICAL LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,117 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PSYENCE BIOMEDICAL LTD finden Sie auf Wallstreet Online.
